Documentation Centre

October 09, 2018
Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOME?. Diabetologia. 2018;61:1522-1527
Zinman B, Inzucchi SE, Wanner C, Hehnke U, George JT, Johansen OE, Fitchett D; EMPA-REG OUTCOME® investigators

Description of this Publication

Consult publication on external website

By clicking on this link, you will leave the INTERNATIONAL CHAIR ON CARDIOMETABOLIC RISK website

Key Words
Cardiovascular Disease, Diabetes, Gender Differences